Study examines outcomes of high-dose antiplatelet drug after stent placement
CHICAGO – Modifying a patient's dosage of the antiplatelet drug clopidogrel for 6 months depending on the patient's level of platelet reactivity did not result in combined lower rates of nonfatal heart attack, stent thrombosis (clot) and cardiovascular death in patients who had a procedure such as balloon angioplasty and received a drug-releasing coronary stent, according to a study in the March 16 issue of JAMA.
Current guidelines recommend treating patients undergoing percutaneous coronary intervention (PCI; procedure such as balloon angioplasty used to open narrowed ...

